Journals / Archives of Clinical and Experimental Medicine / 2019 / Cilt: 4 - Sayı: 3

Effect of palmitate-induced steatosis on paraoxonase-1 and paraoxonase-3 enzymes in human-derived liver (HepG2) cells

İnsan kaynaklı karaciğer (HepG2) hücrelerinde palmitat ile oluşturulan yağlanmanın paraoksonaz-1 ve paraoksonaz-3 enzimlerine etkisi

Pages
142–147
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Our study showed that palmitate-induced steatosis up-regulates paraoxonase-1 mRNA, has no effect on paraoxonase-1 and paraoxonase-3 protein levels, paraoxonase-3 mRNA and arylesterase activity in HepG2 cells.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Palmitate is one of the most abundant fatty acid in both liver of healthy individuals and in patients with non-alcoholic fatty liver disease.
📊
Key Findings & Data:Palmitate-induced steatosis in HepG2 cells is an in vitro non-alcoholic fatty liver disease model to investigate acute harmful effects of fat overaccumulation in the liver.
💡
Conclusion & Impact:Conclusion: Our study showed that palmitate-induced steatosis up-regulates paraoxonase-1 mRNA, has no effect on paraoxonase-1 and paraoxonase-3 protein levels, paraoxonase-3 mRNA and arylesterase activity in HepG2 cells.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Palmitat · paraoksonaz-1 · paraoksonaz-3

Abstract

Aim: Palmitate is one of the most abundant fatty acid in both liver of healthy individuals and in patients with non-alcoholic fatty liver disease. Palmitate-induced steatosis in HepG2 cells is an in vitro non-alcoholic fatty liver disease model to investigate acute harmful effects of fat overaccumulation in the liver. Non-alcoholic fatty liver disease is strongly associated with atherosclerosis. Paraoxonase-1 and paraoxonase-3 are anti-atherosclerotic enzymes which are bound to high density lipoprotein in circulation and they are primarily synthesized by liver. There is no study that investigated the effect of palmitate-induced steatosis on paraoxonase-1 and paraoxonase-3 enzymes. The aim of present study was to investigate the effect of palmitate-induced steatosis on paraoxonase-1 and paraoxonase-3 enzymes in HepG2 cells. Methods: To induce steatosis, cells were incubated with 0.4, 0.7 and 1 mM palmitate for 24 hours. Cell viability was evaluated by 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay. Cells were stained with oil red O and triglyceride levels were measured. Paraoxonase-1 and paraoxonase-3 protein levels were measured by western blotting, their mRNA expression were measured by quantitative PCR and arylesterase activity was measured spectrophotometrically. Results: All palmitate concentrations caused a significant increase on paraoxonase-1 mRNA levels. Palmitate concentrations did not cause a significant change on paraoxonase-1 and paraoxonase-3 protein levels, paraoxonase-3 mRNA levels and arylesterase activities. Conclusion: Our study showed that palmitate-induced steatosis up-regulates paraoxonase-1 mRNA, has no effect on paraoxonase-1 and paraoxonase-3 protein levels, paraoxonase-3 mRNA and arylesterase activity in HepG2 cells.

Özet

Amaç: Palmitat, hem sağlıklı bireylerin hem de non-alkolik karaciğer yağlanması hastalarının karaciğerinde en fazla bulunan yağ asitlerinden biridir. HepG2 hücrelerinde palmitat ile oluşturulan yağlanma, karaciğerdeki yağ birikiminin akut zararlı etkilerinin araştırılmasında kullanılan in vitro non-alkolik yağlı karaciğer hastalığı modelidir. Non-alkolik yağlı karaciğer hastalığı ateroskleroz ile yakından ilişkilidir. Paraoksonaz-1 ve paraoksonaz-3 dolaşımda yüksek dansiteli lipoproteine bağlı anti-aterosklerotik enzimlerdir ve esas olarak karaciğerde sentezlenirler. Palmitat ile oluşturulan yağlanmanın paraoksonaz-1 ve paraoksonaz-3 enzimleri üzerine etkisini araştıran bir çalışma bulunmamaktadır. Bu çalışmanın amacı HepG2 hücrelerinde palmitat ile oluşturulan yağlanmanın paraoksonaz-1 ve paraoksonaz-3 enzimlerine etkisini araştırmaktır.Yöntemler: Yağlanma oluşturmak için hücreler 0.4, 0.7 ve 1 mM palmitat ile 24 saat inkübe edildi. Hücre canlılığı 3-(4,5-Dimetil-2-tiazolil)-2,5-difenil-2H-tetrazolium bromür testi ile değerlendirildi. Hücreler oil red O ile boyandı ve trigliserit düzeyleri ölçüldü. Paraoksonaz-1 ve paraoksonaz-3 protein düzeyleri western blot ile, mRNA’ları ise kantitatif PCR ile ve arilesteraz aktivitesi spektrofotometrik olarak ölçüldü. Bulgular: Tüm palmitat konsantrasyonları paraoksonaz-1 mRNA düzeylerinde anlamlı bir artışa yol açtı. Palmitat konsantrasyonları paraoksonaz-1 ve paraoksonaz-3 protein düzeylerinde, paraoksonaz-3 mRNA düzeylerinde ve arilesteraz aktivitesinde anlamlı bir değişime yol açmadı. Sonuç: Çalışmamız, HepG2 hücrelerinde palmitat ile oluşturulan yağlanmanın paraoksonaz-1 mRNA düzeyini arttırdığını, paraoksonaz-1 ve paraoksonaz-3 protein düzeylerine, paraoksonaz-3 mRNA düzeylerine ve arilesteraz aktivitesine etkisi olmadığını gösterdi.

🔖

Cite This Article

ÖZGÜN, G. S., ÖZGÜN, E., TABAKÇIOĞLU, K., GÖKMEN, S. S., ESKİOCAK, S. (2019). Effect of palmitate-induced steatosis on paraoxonase-1 and paraoxonase-3 enzymes in human-derived liver (HepG2) cells. Archives of Clinical and Experimental Medicine, Cilt: 4 - Sayı: 3, 142–147. https://ajindex.com/articles/142497

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005-23
  2. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer, M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84
  3. DeFilippis AP, Blaha MJ, Martin SS, Reed RM, Jones SR, Nasir K, et al. Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2013;227:429-36
  4. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015; 62: 47-64
  5. Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol. 2008;49:600-07
  6. Araya J, Rodrigo R, Videla LA, Thielemann L, Orellana M, Pettinelli, P et al. Increase in long-chain polyunsaturated fatty acid n - 6/n - 3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond). 2004;106:635-43
  7. Bouma ME, Rogier E, Verthier N, Labarre C, Feldmann G. Further cellular investigation of the human hepatoblastoma-derived cell line HepG2: morphology and immunocytochemical studies of hepatic-secreted proteins. In Vitro Cell Dev Biol. 1989;25:267-75
  8. Gómez-Lechón MJ, Donato MT, Martínez-Romero A, Jiménez N, Castell JV, O'Connor JE. A human hepatocellular in vitro model to investigate steatosis. Chem Biol Interact. 2007;165:106-16
  9. She ZG, Chen HZ, Yan Y, Li H, Liu DP. The human paraoxonase gene cluster as a target in the treatment of atherosclerosis. Antioxid Redox Signal. 2012;16:597-632
  10. Podrez EA. Anti-oxidant properties of high-density lipoprotein and atherosclerosis. Clin Exp Pharmacol Physiol. 2010;37:719-25
  11. Précourt LP, Amre D, Denis MC, Lavoie JC, Delvin E, Seidman E, et al. The three-gene paraoxonase family: physiologic roles, actions and regulation. Atherosclerosis. 2011;214:20-36
  12. Hussein O, Zidan J, Abu Jabal K, Shams I, Szvalb S, Grozovski M, et al. Paraoxonase activity and expression is modulated by therapeutics in experimental rat nonalcoholic Fatty liver disease. Int J Hepatol. 2012;2012:265305
  13. Pereira RR, de Abreu IC, Guerra, JF, Lage NN, Lopes JM, Silva M, et al.